chlorpromazine

Trade name: Thorazine

Small moleculeapproved

Approved

Sep 18, 1957

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups. — NCATS

Clinical trial activity

18 trials · 39 clinical orgs · 51 marketing orgs

Phase 1
6
Phase 2
6
Phase 3
5
Phase 4
4

Earliest trial started Dec 1, 1994 (NCT00169039)

Timeline

1950s

  1. Sep 18, 1957

    Earliest FDA Approval

  2. Sep 18, 1957

    GlaxoSmithKline — NDA Secondary Org

1970s

  1. Mar 16, 1972

    Lederle — Marketing Organization

  2. Mar 16, 1972

    American Cyanamid — Marketing Organization

  3. Jan 3, 1973

    Sandoz — Marketing Organization

  4. Feb 13, 1974

    Watson Pharmaceuticals — Marketing Organization

  5. Feb 13, 1974

    Dr. Reddy's Laboratories — Marketing Organization

  6. May 6, 1974

    Teva — Marketing Organization

  7. Jul 9, 1974

    Upsher-Smith Laboratories — Marketing Organization

  8. Mar 1, 1976

    Fosun — Marketing Organization

  9. Mar 1, 1976

    Allied Pharmaceutical Services — Marketing Organization

  10. Mar 1, 1976

    Saptalis Pharmaceuticals — Marketing Organization

  11. Dec 8, 1977

    Abraxis — Marketing Organization

  12. Feb 6, 1978

    Lumara Health — Marketing Organization

1980s

  1. Aug 13, 1980

    Parke-Davis — Marketing Organization

  2. Aug 13, 1980

    Warner Lambert — Marketing Organization

  3. Nov 7, 1980

    Actavis — Marketing Organization

  4. Nov 10, 1980

    Alpharma — Marketing Organization

  5. Feb 4, 1981

    Wockhardt — Marketing Organization

  6. Dec 14, 1981

    Vanguard — Marketing Organization

  7. Jun 28, 1982

    Puracap Pharmaceutical — Marketing Organization

  8. Sep 16, 1982

    West-Ward Pharmaceutical — Marketing Organization

  9. Apr 27, 1983

    Cycle Pharmaceuticals Ltd. — Marketing Organization

  10. Apr 27, 1983

    Hikma — Marketing Organization

  11. Apr 15, 1988

    Marsam Pharmaceuticals — Marketing Organization

1990s

  1. Jan 26, 1999

    Pharmaceutical Associates — Marketing Organization

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2016

    Cycle Pharmaceuticals Ltd. — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

  3. Sep 10, 2018

    Amneal Pharmaceuticals — Marketing Organization

2020s

  1. Jan 17, 2020

    Zydus Discovery DMCC — Marketing Organization

  2. Jul 7, 2020

    Aurobindo Pharma — Marketing Organization

  3. Jul 7, 2020

    Eugia Pharma — Marketing Organization

  4. Aug 31, 2020

    Appco Pharma — Marketing Organization

  5. Aug 31, 2020

    Mayne Pharma — Marketing Organization

  6. Aug 31, 2020

    Somerset Pharmaceuticals — Marketing Organization

  7. Oct 26, 2020

    Sun Pharmaceuticals — Marketing Organization

  8. Jan 22, 2021

    Lannett Company, Inc. — Marketing Organization

  9. Mar 23, 2021

    Glenmark Pharmaceuticals — Marketing Organization

  10. Jun 2, 2021

    Genus Oncology, LLC — Marketing Organization

  11. Nov 29, 2021

    Enaltec — Marketing Organization

  12. Nov 29, 2021

    ZAMEER PHARMS — Marketing Organization

  13. Nov 29, 2021

    Chartwell Pharmaceuticals — Marketing Organization

  14. Jan 27, 2022

    MSN Laboratories — Marketing Organization

  15. Jul 13, 2023

    Lupin — Marketing Organization

  16. Jul 18, 2023

    Alembic — Marketing Organization

  17. Sep 24, 2024

    Deva Holding A.S. — Marketing Organization

  18. Oct 4, 2024

    Gland Pharma Ltd — Marketing Organization

  19. Nov 18, 2024

    Aspiro — Marketing Organization

  20. Dec 10, 2024

    THINQ Pharma CRO Ltd. — Marketing Organization

  21. Oct 10, 2025

    Rubicon Research — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedSep 18, 1957

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
Mol. weight
318.87 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

Yes

Black box warning

Sources

Also known as

  • 2-chloropromazine
  • 3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethyl-1-propanamine
  • 3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethyl-1-propanamine
  • 3-(2-chlorophenothiazin-10-yl)-n,n-dimethyl-propan-1-amine
  • 3-(2-chlorophenothiazin-10-yl)-n,n-dimethyl-propan-1-amine
  • aminazine
  • aminazine
  • chloractil
  • chloractil
  • chlorazine
  • chlorazine
  • chlordelazin
  • chlorderazin
  • chlorderazin
  • chlorderazin
  • chloropromazine
  • chloropromazine
  • chlorpromados
  • chlorpromados
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine
  • chlorpromazine hcl
  • chlorpromazine hcl
  • chlorpromazine hcl
  • chlorpromazine hibenzate
  • chlorpromazine hydrochloride
  • chlorpromazine hydrochloride
  • chlorpromazine hydrochloride
  • chlorpromazine hydrochloride
  • chlorpromazine hydrochloride
  • chlorpromazine hydrochloride intensol
  • chlorpromazine hydrochloride intensol
  • chlorpromazine phenolphthalinate
  • chlorpromazine phenolphthalinate
  • chlorpromazine tannate
  • chlorpromazine tannate
  • chlorpromazinum
  • chlorpromazinum
  • clorpromazina
  • clorpromazina
  • contomin
  • contomin
  • contomin
  • cpz
  • cpz
  • elmarin
  • elmarin
  • largactil
  • largactil
  • largactil fte
  • megaphen
  • megaphen
  • n-(3-dimethylaminopropyl)-3-chlorophenothiazine
  • n-(3-dimethylaminopropyl)-3-chlorophenothiazine
  • promapar
  • promapar
  • rimazine
  • sonazine
  • sonazine
  • thorazine
  • thorazine
  • thorazine
  • thorazine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06663631Phase 1Nov 30, 2024Capital Medical University, Linyi People's Hospital
NCT05431595Phase 2/Phase 3 (Phase 3)Dec 30, 2022State of Texas, University of Texas at Houston
NCT05433402Phase 1/Phase 2 (Phase 2)Jul 20, 2022Sadat City University
NCT05190315Phase 1Jan 28, 2022University of Iowa
NCT04354805Phase 1/Phase 2 (Phase 2)May 31, 2020Cairo University
NCT04366739Phase 3Apr 29, 2020Centre Hospitalier St Anne, Service Hospitalo-Universitaire - GHU PARIS Psychiatrie & Neurosciences, University of Paris
NCT04224441Phase 2Dec 15, 2019Carlo Besta Neurological Institute, Istituto Oncologico Veneto IRCCS, ISTITUTO REGINA ELENA
NCT06154434Phase 1Dec 6, 2018Chonbuk National University, Whanin Pharmaceutical Company
NCT03639558Phase 4Aug 28, 2018Croix-Rousse Hospital, Lyon, University of Nottingham
NCT03183310N/AJul 1, 2017Katholieke Universiteit Leuven
NCT03021486Phase 2/Phase 3 (Phase 3)Jun 5, 2017National Institutes of Health (NIH), University of Texas at Houston
NCT02943213Phase 1Nov 1, 2016Cycle Pharmaceuticals Ltd., Parexel
NCT01404364N/AJan 1, 2010Hospital Governador Celso Ramos
NCT00882518Phase 3Apr 1, 2009AstraZeneca, Jiao Tong University
NCT00654576Phase 4Feb 1, 2005Capital Medical University, Central South University, Chongqing Medical University, Guangzhou Medical University, Henan Medical University, Hunan Mental Hospital, Jiangxi Mental Hospital, Jiao Tong University, Nanjing Medical University, Sichuan University
NCT00202293Phase 4Oct 1, 2001Melbourne Health, University of Lausanne
NCT02810782Phase 3Jun 1, 2001University of Zurich
NCT00169039Phase 4Dec 1, 1994Dartmouth University, Harvard University, National Institute of Mental Health (NIMH), Novartis
Showing 18 of 18 trials
Page 1 / 1

Organizations

Research & Development (39)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Capital Medical UniversityAcademic/Hospital2122005
Jiao Tong UniversityAcademic/Hospital2022005
University of Texas at HoustonAcademic/Hospital2212017
AstraZenecaFor profit1112009
Cairo UniversityAcademic/Hospital1112020
Carlo Besta Neurological InstituteAcademic/Hospital1012019
Central South UniversityAcademic/Hospital1112005
Centre Hospitalier St AnneAcademic/Hospital1112020
Chonbuk National UniversityAcademic/Hospital1012018
Chongqing Medical UniversityAcademic/Hospital1012005
Croix-Rousse Hospital, LyonAcademic/Hospital1112018
Cycle Pharmaceuticals Ltd.For profit1112016
Dartmouth UniversityAcademic/Hospital1011994
Guangzhou Medical UniversityAcademic/Hospital1012005
Harvard UniversityAcademic/Hospital1111994
Henan Medical UniversityAcademic/Hospital1012005
Hospital Governador Celso RamosAcademic/Hospital1112010
Hunan Mental HospitalAcademic/Hospital1012005
Istituto Oncologico Veneto IRCCSAcademic/Hospital1012019
ISTITUTO REGINA ELENAAcademic/Hospital1112019
39 organizations
Page 1 / 2

Marketing (59)

OrganizationOrg typeRelationshipDate
AbbottFor profitMKTG
AbraxisFor profitMKTGDec 8, 1977
ActavisFor profitMKTGNov 7, 1980
AlembicFor profitMKTGJul 18, 2023
Allied Pharmaceutical ServicesFor profitMKTGMar 1, 1976
AlpharmaFor profitMKTGNov 10, 1980
American CyanamidFor profitMKTGMar 16, 1972
American Home ProductsFor profitMKTG
Amneal PharmaceuticalsFor profitMKTGSep 10, 2018
Appco PharmaFor profitMKTGAug 31, 2020
AspiroFor profitMKTGNov 18, 2024
Aurobindo PharmaFor profitMKTGJul 7, 2020
Chartwell PharmaceuticalsFor profitMKTGNov 29, 2021
Cycle Pharmaceuticals Ltd.For profitMKTGApr 27, 1983
Deva Holding A.S.For profitMKTGSep 24, 2024
Dr. Reddy's LaboratoriesFor profitMKTGFeb 13, 1974
EnaltecFor profitMKTGNov 29, 2021
Eugia PharmaFor profitMKTGJul 7, 2020
FosunFor profitMKTGMar 1, 1976
Genus Oncology, LLCFor profitMKTGJun 2, 2021
Gland Pharma LtdFor profitMKTGOct 4, 2024
Gland Pharma LtdFor profitSYNOct 4, 2024
GlaxoSmithKlineFor profitNDA2Sep 18, 1957
Glenmark PharmaceuticalsFor profitMKTGMar 23, 2021
HikmaFor profitMKTGApr 27, 1983
HikmaFor profitSYNApr 27, 1983
Lannett Company, Inc.For profitMKTGJan 22, 2021
LederleFor profitMKTGMar 16, 1972
Lumara HealthFor profitMKTGFeb 6, 1978
LupinFor profitMKTGJul 13, 2023
MSN LaboratoriesFor profitMKTGJan 27, 2022
Marsam PharmaceuticalsFor profitMKTGApr 15, 1988
Mayne PharmaFor profitMKTGAug 31, 2020
MylanFor profitMKTG
Parke-DavisFor profitMKTGAug 13, 1980
Pharmaceutical AssociatesFor profitMKTGJan 26, 1999
Puracap PharmaceuticalFor profitMKTGJun 28, 1982
Rubicon ResearchFor profitMKTGOct 10, 2025
SandozFor profitMKTGJan 3, 1973
Saptalis PharmaceuticalsFor profitMKTGMar 1, 1976
Smith, Kline & FrenchFor profitNDA
Somerset PharmaceuticalsFor profitMKTGAug 31, 2020
Sun PharmaceuticalsFor profitMKTGOct 26, 2020
Sun PharmaceuticalsFor profitSYNOct 26, 2020
THINQ Pharma CRO Ltd.For profitMKTGDec 10, 2024
TevaFor profitMKTGMay 6, 1974
TevaFor profitMKTGOct 25, 2021
Upsher-Smith LaboratoriesFor profitMKTGJul 9, 1974
Upsher-Smith LaboratoriesFor profitSYNJul 9, 1974
VanguardFor profitMKTGDec 14, 1981
Warner LambertFor profitMKTGAug 13, 1980
Watson PharmaceuticalsFor profitMKTGFeb 13, 1974
West-Ward PharmaceuticalFor profitMKTGSep 16, 1982
West-Ward PharmaceuticalFor profitSYNJul 25, 1974
WockhardtFor profitMKTGFeb 4, 1981
ZAMEER PHARMSFor profitMKTGNov 29, 2021
Zydus Discovery DMCCFor profitMKTGJan 17, 2020
Zydus Discovery DMCCFor profitSYNMar 13, 2024
Zydus Discovery DMCCFor profitSYNJan 17, 2020